Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3

D. P. Modest, T. Denecke, J. Pratschke, I. Ricard, H. Lang, M. Bemelmans, T. Becker, M. Rentsch, D. Seehofer, C. J. Bruns, B. Gebauer, H. I. Modest, S. Held, G. Folprecht, V. Heinemann, U. P. Neumann

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)77-86
Number of pages10
JournalEuropean Journal of Cancer
Volume88
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • Metastatic colorectal cancer
  • Resection
  • Conversion therapy
  • Cetuximab
  • Bevacizumab
  • Surgery
  • EXPERT CONSENSUS STATEMENT
  • LIVER METASTASES
  • PHASE-3 TRIAL
  • OPEN-LABEL
  • RESECTION
  • SURVIVAL
  • SURGERY
  • HEPATECTOMY
  • THERAPIES
  • DISEASE

Cite this

Modest, D. P., Denecke, T., Pratschke, J., Ricard, I., Lang, H., Bemelmans, M., Becker, T., Rentsch, M., Seehofer, D., Bruns, C. J., Gebauer, B., Modest, H. I., Held, S., Folprecht, G., Heinemann, V., & Neumann, U. P. (2018). Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. European Journal of Cancer, 88, 77-86. https://doi.org/10.1016/j.ejca.2017.10.028